The selective BTK inhibitor zanubrutinib (Brukinsa) has been approved by the TGA for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL). Both groups of patients will have immediate access to the drug through a BeiGene sponsored post-approval, pre-reimbursement access program. Zanubrutinib has been approved for WM patients who have ...
Second generation BTK inhibitor gets TGA nod
By Mardi Chapman
11 Oct 2021